Bionyra Pharma's Series A Funding Success

Bionyra Pharma, a clinical-stage biopharmaceutical company, has successfully secured $165 million in a Series A funding round. This significant financial boost is aimed at advancing their portfolio of next-generation biologics designed to treat immune-mediated inflammatory diseases. The round was co-led by Jeito Capital and Sofinnova Partners, with additional participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.

Company Focus and Pipeline

Bionyra Pharma is dedicated to developing innovative treatments for diseases where current options fall short, such as atopic dermatitis and inflammatory bowel disease. The company is currently advancing a pipeline of clinical and near-clinical anti-inflammatory therapies. These therapies are designed to enhance disease control through multi-pronged biological approaches combined with optimized pharmacokinetics.

Among the key developments in Bionyra's pipeline are:

  • BYN-002: A TL1A monoclonal antibody featuring half-life extension technology, which is being developed for inflammatory bowel disease and other TL1A-related conditions. This candidate has already completed Phase 1 enrollment in healthy subjects.
  • BYN-003: A TL1A and IL-23p19 bispecific antibody, also with half-life extension technology, entered clinical trials in April, and its Phase 1 study is currently underway.
  • BYN-001: An IL-25 monoclonal antibody in the IND-stage for atopic dermatitis and Type 2 inflammation.

Bionyra has licensed BYN-002 and BYN-003 from TrueLab Biopharmaceutical and BYN-001 from NovaRock Biotherapeutics, securing exclusive global rights outside of Greater China.

Use of Funds

The recently acquired funds will primarily support the advancement of Bionyra's clinical-stage pipeline. The company aims to build a strong foundation around therapies that promise deeper and more durable disease control. This includes progressing additional preclinical assets, some of which have been sourced from TrueLab Biopharmaceutical.

Leadership and Strategic Board Expansion

With this new influx of capital, Bionyra is also expanding its strategic leadership. As part of the financing deal, several new members will join Bionyra's Board of Directors, bringing valuable insights and guidance. These new members include Mehdi Ainouche from Jeito Capital, Anta Gkelou from Sofinnova Partners, Avital Adler from Arkin Bio, and Laia Crespo from Sanofi Ventures.

Conclusion

Bionyra Pharma's successful Series A funding round marks a pivotal step in its mission to provide better treatment options for patients with immune-mediated inflammatory diseases. With strong financial backing and an expanding leadership team, Bionyra is well-positioned to make significant advancements in the field of biologics.